p38 MAP kinase inhibitors: Many are made, but few are chosen

Current Opinion in Drug Discovery and Development

Volumn 8, Issue 4, 2005, Pages 421-430

  Dominguez, Celia ^a   Powers, David A ^a   Tamayo, Nuria ^a  

^a AMGEN INC   (United States)

Author keywords

Cytokine biosynthesis; Enbrel ; IL 1 ; Kineret ; MAPK p38; Psoriasis; Rheumatoid arthritis; TNF

Indexed keywords

AMG 548; DORAMAPIMOD; ETANERCEPT; IMIDAZOLE DERIVATIVE; INTERLEUKIN 1BETA; ISOENZYME; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 11; MITOGEN ACTIVATED PROTEIN KINASE 12; MITOGEN ACTIVATED PROTEIN KINASE 13; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PYRIDINE DERIVATIVE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SCIO 323; SCIO 469; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VX 702;

CLINICAL TRIAL; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LOCALIZATION; HEMATOPOIETIC CELL; HUMAN; INFLAMMATION; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS; ENZYME INHIBITORS; HUMANS; INDOLES; MODELS, MOLECULAR; P38 MITOGEN-ACTIVATED PROTEIN KINASES;

EID: 21544434331     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Foster ML, Halley F, Souness JE: Potential of p38 inhibitors in the treatment of rheumatoid arthritis. Drug News Perspect (2000) 13(8):488-497.
2. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF et al: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology (1999) 117(4):761-769.
3. Arend WP, Dayer JM: Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum (1990) 33(3):305-315.
4. Firestein GS, Alvaro-Gracia JM, Maki R: Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol (1990) 144(9):3347-3353.
5. Ulfgren AK, Andersson U, Engstrom M, Klareskog L, Maini RN, Taylor PC: Systemic anti-tumor necrosis factor α therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor α synthesis. Arthritis Rheum (2000) 43(11):2391-2396.
6. Ritchlin C: Fibroblast biology. Effector signals released by the synovial fibroblast in arthritis. Arthritis Res (2000) 2(5):356-360.
7. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Roy M, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ et al: Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial. Ann Intern Med (1999) 130(6):478-486.
8. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, Woody JN: Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 344(8930):1105-1110.
9. van de Putte LBA, Rau R, Breedveld FC, Kalden JR, Malaise MG, Schattenkirchner M, Emery P, Burmester GR, Zeidler H, Moutsopoulos HH, Compagnone D et al: Efficacy of the fully human anti-TNF antibody D2E7 in rheumatoid arthritis. Arthritis Rheum (1999) 42(Suppl):S400.
10. Cohen SB, Woolley JM, Chan W: Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. J Rheumatol (2003) 30(2):225-231.
11. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB: Etanercept as monotherapy in patients with psoriasis. N Engl J Med (2003) 349(21):2014-2022.
12. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, Bala M, Marano CW, Menter A: Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol (2004) 51(4):534-542.
13. Paul A, Wilson S, Belham CM, Robinsson CJ, Scott PH, Gould GW, Plevin R: Stress-activated protein kinases: Activation, regulation and function. Cell Signal (1997) 9(6):403-410.
14. Newton R, Holden N: Inhibitors of p38 mitogen-activated protein kinase: Potential as anti-inflammatory agents in asthma? BioDrugs (2003) 17(2):113-129. Review of the nomenclature and signaling cascade of p38 MAPK, and discussion of its impact on inflammation and asthma.
15. Lee JC, Kassis S, Kumar S, Badger A, Adams JL: p38 mitogen-activated protein kinase inhibitors - mechanism and therapeutic potentials. Pharmacol Ther(1999) 82(2-3):389-397.
16. Shi Y, Gaestel M: In the cellular garden of forking paths: How p38 MAPKs signal for downstream assistance. Biol Chem (2002) 383(10):1519-1536.
17. Han J, Lee JD, Jiang Y, Li Z, Feng L, Ulevitch RJ: Characterization of the structure and function of a novel MAP kinase kinase (MKK6). J Biol Chem (1996) 271(6):2886-2891.
18. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW et al: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature (1994) 372(6508):739-746. Describes the discovery of the molecular target for aryl-pyridyl-imidazole anti-inflammatory agents.
19. Vertex Pharmaceutical Inc: Vertex moves to re-allocate resources from VX-745 in p38 map kinase program to accelerate development of second generation drug candidates VX-702 and VX-850. Press Release (2001) September 24. http://www.vrtx.com/Pressreleases2001/ pr092401.html
20. IDdb drug reference 401259: Drug development update - keliximab, pexiganan, SB-209247, SB-218842, SB-240683, SB-242235, glaspomid, levcromakalim. MAGE-3 anticancer vaccine, HIV vaccine, hepatitis E vaccine, extra strength hepatitis B vaccine and malaria vaccine. Company Communication (2001) March 08. http://www.iddb3.com/iddb3/iddb3_2/reports.display?id=401259&templa te=Reference&i_query_id=5112426
21. Regan J: The identification of BIRB-796, an inhibitor of p38 MAP kinase: Four pivotal discoveries. Drew Residential School on Medicinal Chemistry. Madison, NJ, USA (2004).
22. Zack D, Campagnuolo GS, Middleton S, Koch A, Zhu L, Bolon B, Feige U: Efficacy of AMG-548, a novel p38 kinase inhibitor, in rats with adjuvant-induced or collagen-induced arthritis. 66th American College of Rheumatology Meeting, Orlando, FL, USA (2003).
23. Dominguez C, Liu L, Zhang D, Tamayo N, Powers D, Wong M, Feige U, Harris R, Wild S, Neervannan S, Syed R et at. p38 MAP kinase: An exciting target for the treatment of inflammatory diseases. 228th American Chemical Society Meeting, Philadelphia, PA, USA (2004):MEDI-189.
24. Regan J, Breitfelder S, Cirillo P, Gilmore T, Graham AG, Mickey E, Klaus B, Madwed J, Moriak M, Moss N, Pargellis C et al: Pyrazole urea-based inhibitors of p38 MAP kinase: From lead compound to clinical candidate. J Med Chem (2002) 45(14):2994-3008.
25. Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, Graham AG, Grob PM, Hickey ER, Moss N, Pav S, Regan J: Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol (2002) 9(4):268-272. Presents the X-ray co-crystal structures of p38α protein with a 'DGF-out' allosteric p38 inhibitor and p38α protein with BIRB-796.
26. Madwed J: Biochemical and pharmacological evaluation of a selective p38 inhibitor. IBC Protein Kinase Conference, San Diego, CA, USA (2002).
27. Polmar SH, Yong CL, Wood CC, Staehle H, Gupta A: Safety and pharmacokinetics of an oral p38 MAP kinase inhibitor (BIRB 796 BS), administered twice daily for 14 days to healthy volunteers. J Allergy Clin Immun (2002) 109(Suppl 1):S66.
28. Johnson & Johnson Co Ltd: Johnson & Johnson completes acquisition of Scios Inc. Press Release (2003) April 29. http://www.jnj.com/news/jnj_news/ 20030429_120809.htm
29. Mavunkel BJ, Chakravarty S, Perumattam JJ, Luedtke GR, Liang X, Lim D, Xu YJ, Laney M, Liu DY, Schreiner GF, Lewicki JA et al: Indole-based heterocyclic inhibitors of p38α MAP kinase: Designing a conformationally restricted analogue. Bioorg Med Chem Lett (2003) 13(18):3087-3090.
30. Cirillo PF, Pargellis C, Regan J: The non-diaryl heterocycle classes of p38 MAP kinase inhibitors. Curr Top Med Chem (2002) 2(9):1021-1035.
31. Schreiner G: The role of selectivity in the clinical development of p38 kinase inhibitors. IBC Protein Kinases Conference, San Diego, CA, USA (2002).
32. Nguyen AN, Reddy M, Henson M, Stebbins EG, O'Young G, Ma JY, Hghnazari E, Kapoun AM, Medicherla S, Protter A, Higgins LS et al: SCIO-469, a potent and selective inhibitor of p38α MAPK, normalizes the bone marrow micro-enviroment and inhibits multiple myeloma cell proliferation in in vitro and in vivo models. 46th American Society of Hematology Meeting, San Diego, CA, USA (2004):Abs 1501.
33. Scios Inc: Scios p38 MAP kinase inhibitor data presented at the American College of Rheumatology Scientific Meeting. Press Release (2002) October 28. http://www.sciosinc.com/scios/pr_ 1046375375
34. Mavunkel B, Chakravaty S, Perumattam J, Liu D, Luedtke G, Qing L, Dugar S, Laney M, Henson M, Xu Y-J, Schreiner G et al: Discovery and biological evaluation of p38α MAP kinase inhibitor SX-011. International Symposium on Advances in Synthetic, Combinatorial and Medicinal Chemistry, Moscow, Russia (2004).
35. Study of oral SCIO-469 in relapsed, refractory patients with multiple myeloma. ClinicalTrails.gov. Bethesda, MD, USA (2005). http://www. clinicaltrials.gov/ct/show/NCT00087867?order=3
36. Tong MD, Daniels DO, Montano T, Chang S, Desjardins P: SCIO-469, a novel P38A MARK Inhibitor, provides efficacy in acute postsurgical dental pain. Clin Pharm Ther (2004) 75(2):3.
37. IDdb drug report: SCIO-323. Thomson Scientific Ltd, London, UK. http://www.iddb3.com/iddb3/iddb3_2/reports.display?id=40816&templat e=Drug&i_query_id=5075022
38. 110 flip in the linker region of p38α bound with VX-745.
39. Vertex Pharmaceutical Inc: Preliminary phase IIa data for VX-702 demonstrate tolerability and reduction in C-reactive protein in cardiovascular patients. Press Release (2004) October 18. http://www.vpharm.com/ Pressreleases2004/pr101804.html
40. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S: The protein kinase complement of the human genome. Science (2002) 298(5600):1912-1934.
41. AMGEN INC (Spohr UD, Malone MJ, Mantlo NB): Substituted pyrimidinone and pyridone compounds and methods of use. US-06096753 (2000).
42. BOEHRINGER INGELHEIM PHARMACEUTICALS INC (Grob PM, Madwed JB, Pargellis C, Yong CL): Method for administering BIRB 796 BS. WO-03049742 (2003). Provides details of a phase I multi-dose study and an in vivo LPS challenge in monkey and human with BIRB-796.
43. SCIOS INC (Mavunkel BJ, Chakavarty S, Perumattan JJ, Dugar S, Lu Q, Liang, X): Indole derivatives as inhibitors of p38 kinase. WO-00071535 (2000).
44. SCIOS INC (Mavunkel BJ, Liu DY, Schreiner GF, Lewicki JA): Compounds and methods to treat cardiac failure and other disorders. WO-00059904 (2000).
45. SCIOS INC (Goehring RR, Luedtke GR, Mavunkel BJ, Chakravarty S, Dugar S, Schreiner GF, Liu DY, Lewicki JA): Inhibitors of p38-α kinase. WO-00012074 (2000).
46. SCIOS INC (Dugar S, Luedtke G, Tan X): Novel indole derivatives useful as p38α kinase inhibitors. WO-00242292 (2002).
47. SCIOS INC (Dugar S, Perumattan J, Tester R, Lu Q): Piperidine/piperazine- type inhibitors of p38 kinase. WO-00246158 (2002).
48. SCIOS INC (Chakravarty S, Dugar S, Lu Q, Luedtke GR, Mavunkel BJ, Perumattan JJ, Tester R): Indole-type derivatives as inhibitors of p38 kinase. WO-2004022712 (2004).
49. SCIOS INC (Protter AA, Svensson C, Yaksh T, Cordell B, Dugar S): Treatment of pain by inhibition of p38 MAP kinase. WO-2004021988 (2004).
50. VERTEX PHARMACEUTICALS INC (Salituro F, Bemis G, Cochran J): Inhibitors of p38. WO-00017175 (2000).
51. VERTEX PHARMACEUTICALS INC (Salituro F, Bemis G, Evindar G): Pyridine derivatives as inhibitors of p38. WO-00170695 (2001).